Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 140

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 140
---
 cell carcinoma (NCT04854499), solid tumors (NCT04827576), triple-negative breast cancer (NCT04958785), and colorectal cancer (NCT05330429). Although enrollment is paused, patients already enrolled and deriving clinical benefit may continue treatment after re-consenting. |

Despite its potential, Magrolimab’s clinical development has been significantly hampered by challenges such as anemia caused by red blood cell binding, which remains a major safety concern. These setbacks highlight the need for improved CD47-targeting strategies, emphasizing the importance of addressing both efficacy and safety issues to realize the therapeutic promise of this target. In contrast, our CD47 program has been designed specifically to avoid RBC binding and prevent anemia, a common side effect seen with first-generation CD47 inhibitors. This key advantage has been initially demonstrated through in vitro experiments using human blood and in vivo toxicity studies in monkeys, further supporting its safety profile. In addition, the strong results from our preclinical in vivo studies show that when our CD47 antibody is combined not only with already marketed PD-1/PD-L1 blockades but also with T

89

cell boosters like LAG-3, TIGIT, TIM-3, and ICOS blockades, which are currently in active clinical development, it demonstrates a powerful synergistic effect. This versatility suggests significant market expansion potential as it could enhance the efficacy of various immune checkpoint inhibitors across multiple indications.

Figure 4: Second generation anti-CD47 monoclonal antibodies leading immuno-oncology drug development targeting innate immunity

<div align='center'>90</div>

DIRECTORS AND EXECUTIVE OFFICERS Executive Officers and Directors Our directors and executive officers are as follows:

| Name                           |   | Age |   | Position                             |
| Chris Kim                      | ​ |  65 | ​ | Chief Executive Officer and Director |
| Scott Dam                      | ​ |  46 | ​ | Chief Financial Officer              |
| Byong C. Yoo, PhD              | ​ |  53 | ​ | Chief Science Officer                |
| Sang-jin Daniel Lee, PhD       | ​ |  57 | ​ | Head of Research & Development       |
| Beom K. Choi                   | ​ |  53 | ​ | Chief Technology Officer             |
| Eun Sook Lee, MD, PhD(1)(2)(3) | ​ |  62 | ​ | Independent Director                 |
| Nicholas Fernandez(1)(2)(3)